Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
168 studies found for:    "Adenocarcinoma of the appendix"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Unknown  Non Ivasive Prenatal Diagnosis (NIPD) of Cystic Fibrosis
Condition: Noninvasive Mucinous Cystadenocarcinoma of Ovary
Intervention: Other: A sampling of blood
2 Recruiting Crossover Trial of Systemic Chemotherapy in Patients With Metastatic Well-Differentiated Mucinous Appendiceal Adenocarcinomas With Pseudomyxoma Peritonei
Condition: Gastrointestinal Neoplasms
Intervention: Behavioral: Questionnaire
3 Recruiting Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis
Condition: Cancer
Intervention: Drug: systemic chemotherapy
4 Completed Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
Conditions: Ovarian Clear Cell Cystadenocarcinoma;   Stage III Ovarian Cancer;   Stage IV Ovarian Cancer
Interventions: Drug: Carboplatin;   Drug: Docetaxel;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Drug: Temsirolimus
5 Active, not recruiting
Has Results
Selumetinib in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer
Conditions: Borderline Ovarian Surface Epithelial-stromal Tumor;   Ovarian Serous Cystadenocarcinoma;   Primary Peritoneal Cavity Cancer;   Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor
Interventions: Drug: selumetinib;   Other: pharmacological study;   Other: laboratory biomarker analysis
6 Terminated Endoscopic Ultrasound (EUS) Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm
Conditions: Mucinous Cystic Tumor With Moderate Dysplasia;   Mucinous Cystadenoma of Pancreas;   Mucinous Cystadenocarcinoma of Pancreas;   Benign Neoplasm of Pancreas
Intervention: Drug: Ethanol and Paclitaxel Injection
7 Completed Edrecolomab in Treating Patients With Stage II Colon Cancer
Conditions: Mucinous Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Colon;   Stage IIA Colon Cancer;   Stage IIB Colon Cancer;   Stage IIC Colon Cancer
Interventions: Biological: edrecolomab;   Other: laboratory biomarker analysis
8 Not yet recruiting Proof-of-concept Study of Birinapant in Combination With Platinum Based Chemotherapy in Subjects With High Grade Serous Carcinomas
Condition: Advanced Newly Diagnosed or Recurrent High Grade Serous Carcinomas (HGSC)
Interventions: Drug: Birinapant;   Drug: Paclitaxel;   Drug: Carboplatin
9 Recruiting A Phase II Evaluation of Afatinibin Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma
Condition: HER2/Neu+ Uterine Serous Carcinoma
Intervention: Drug: Afatinib
10 Active, not recruiting Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers
Condition: Advanced GI Cancer
Intervention: Drug: MK-3475
11 Active, not recruiting Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
Conditions: Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions: Biological: aflibercept;   Drug: oxaliplatin;   Drug: leucovorin;   Drug: fluorouracil;   Other: Correlative Studies;   Procedure: DCE MRI;   Radiation: f18FDG-PET;   Procedure: PET (positron emission tomography)
12 Withdrawn Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer
Conditions: Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage I Colon Cancer;   Stage I Rectal Cancer
Interventions: Dietary Supplement: cholecalciferol;   Procedure: biopsy;   Genetic: protein expression analysis;   Other: enzyme-linked immunosorbent assay;   Other: laboratory biomarker analysis;   Genetic: reverse transcriptase-polymerase chain reaction
13 Not yet recruiting Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Conditions: Acinar Cell Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Appendix Mucinous Adenocarcinoma;   Bladder Adenocarcinoma;   Bronchioloalveolar Carcinoma;   Cervical Adenocarcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Endometrial Adenocarcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Fallopian Tube Adenocarcinoma;   Fibromyxoid Tumor;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Skin Neoplasm;   Malignant Testicular Sex Cord-Stromal Tumor;   Metastatic Malignant Neoplasm of Unknown Primary Origin;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Placental-Site Gestational Trophoblastic Tumor;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Malignant Transformation;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Undifferentiated Gastric Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Adenocarcinoma;   Vulvar Squamous Cell Carcinoma
Interventions: Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
14 Terminated Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery
Conditions: Mucinous Adenocarcinoma of the Rectum;   Stage IIA Rectal Cancer;   Stage IIB Rectal Cancer;   Stage IIC Rectal Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Rectal Cancer
Interventions: Drug: paricalcitol;   Radiation: radiation therapy;   Other: laboratory biomarker analysis;   Drug: fluorouracil
15 Withdrawn Research Study in Patients With Advanced Ovarian Epithelial Cancer
Conditions: Ovarian Serous Cystadenocarcinoma;   Ovarian Serous Surface Papillary Adenocarcinoma;   Stage IIIA Ovarian Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIC Ovarian Cancer;   Stage IV Ovarian Cancer
Interventions: Genetic: Comparative Genomic Hybridization;   Other: Laboratory Biomarker Analysis;   Genetic: Polymerase Chain Reaction
16 Active, not recruiting Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Bortezomib;   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
17 Terminated Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer
Conditions: Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Primary Peritoneal Carcinoma;   Stage III Ovarian Cancer;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Carboplatin;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Paclitaxel;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Topotecan Hydrochloride
18 Completed Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer
Conditions: Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Drug: paclitaxel;   Drug: cisplatin;   Drug: topotecan hydrochloride;   Biological: filgrastim
19 Active, not recruiting Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Biological: denileukin diftitox;   Procedure: intraperitoneal administration;   Other: laboratory biomarker analysis;   Other: enzyme-linked immunosorbent assay;   Other: flow cytometry
20 Completed TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Conditions: Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: TLR8 Agonist VTX-2337;   Other: Diagnostic Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Drug: Paclitaxel

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.